2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32026-08-26NCT04437511
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndromeActive, not recruitingPhase 32026-05-27NCT04951219